Creative Medical Technology (OTCMKTS:CELZ) Versus Genocea Biosciences (NASDAQ:GNCA) Head-To-Head Comparison
Creative Medical Technology (OTCMKTS:CELZ) Versus Genocea Biosciences (NASDAQ:GNCA) Head-To-Head Comparison
Genocea Biosciences (NASDAQ:GNCA – Get Rating) and Creative Medical Technology (OTCMKTS:CELZ – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability and risk.
基因生物科技(纳斯达克：GNCA-GET评级)和创新医疗科技(OTCMKTS：CELZ-GET评级)都是小盘医疗公司，但哪只股票更好？我们将根据分析师的建议、估值、机构所有权、股息、收益、盈利能力和风险对这两家公司进行对比。
Profitability
盈利能力
This table compares Genocea Biosciences and Creative Medical Technology's net margins, return on equity and return on assets.
此表比较了Genocea Biosciences和Creative Medical Technology的净利润率、股本回报率和资产回报率。
| Net Margins | Return on Equity | Return on Assets | |
| Genocea Biosciences | N/A | -182.88% | -62.76% |
| Creative Medical Technology | -9,516.90% | -48.25% | -46.65% |
| 净利润率 | 股本回报率 | 资产回报率 | |
| Genocea生物科学 | 不适用 | -182.88% | -62.76% |
| 创新医疗技术 | -9,516.90% | -48.25% | -46.65% |
Valuation and Earnings
估值和收益
This table compares Genocea Biosciences and Creative Medical Technology's revenue, earnings per share (EPS) and valuation.
此表比较了Genocea Biosciences和Creative Medical Technology的收入、每股收益(EPS)和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Genocea Biosciences | $1.64 million | 0.28 | -$33.20 million | ($0.61) | -0.01 |
| Creative Medical Technology | $90,000.00 | 61.25 | $19.21 million | N/A | N/A |
| 总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
| Genocea生物科学 | 164万美元 | 0.28 | -3320万美元 | ($0.61) | -0.01 |
| 创新医疗技术 | $90,000.00 | 61.25 | 1,921万美元 | 不适用 | 不适用 |
Institutional & Insider Ownership
机构与内部人持股
9.3% of Genocea Biosciences shares are held by institutional investors. Comparatively, 10.7% of Creative Medical Technology shares are held by institutional investors. 1.6% of Genocea Biosciences shares are held by company insiders. Comparatively, 2.8% of Creative Medical Technology shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Genocea Biosciences 9.3%的股份由机构投资者持有。相比之下，创新医疗科技10.7%的股份由机构投资者持有。Genocea Biosciences 1.6%的股份由公司内部人士持有。相比之下，创新医疗技术公司2.8%的股份由公司内部人士持有。强大的机构持股表明，捐赠基金、对冲基金和大型基金管理公司相信，一家公司有望实现长期增长。
Analyst Ratings
分析师评级
This is a breakdown of recent recommendations for Genocea Biosciences and Creative Medical Technology, as provided by MarketBeat.com.
这是由MarketBeat.com提供的关于基因生物科学和创新医疗技术的最新建议的细目。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Genocea Biosciences | 0 | 2 | 0 | 0 | 2.00 |
| Creative Medical Technology | 0 | 0 | 1 | 0 | 3.00 |
| 销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
| Genocea生物科学 | 0 | 2 | 0 | 0 | 2.00 |
| 创新医疗技术 | 0 | 0 | 1 | 0 | 3.00 |
Genocea Biosciences presently has a consensus price target of $3.00, suggesting a potential upside of 37,874.68%. Creative Medical Technology has a consensus price target of $10.00, suggesting a potential upside of 2,453.63%. Given Genocea Biosciences' higher probable upside, equities research analysts clearly believe Genocea Biosciences is more favorable than Creative Medical Technology.
Genocea Biosciences目前的共识目标价为3.00美元，这意味着潜在的上涨幅度为37,874.68%。创新医疗技术公司的一致目标价为10.00美元，这意味着潜在的上涨幅度为2,453.63%。鉴于Genocea Biosciences更有可能上行，股票研究分析师显然认为Genocea Biosciences比Creative Medical Technology更有利。
Summary
摘要
Creative Medical Technology beats Genocea Biosciences on 8 of the 11 factors compared between the two stocks.
在两只股票的11个指标中，创新医疗技术公司有8个指标超过了Genocea Bioscions。
About Genocea Biosciences
关于Genocea生物科学
(Get Rating)
(获取评级)
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts.
生物制药公司Genocea Biosciences，Inc.发现和开发新的癌症免疫疗法。该公司使用其专有的发现平台ATLAS，该平台描述了每个患者对下一代肿瘤测序确定的每个目标或抗原的CD4+和CD8+T细胞免疫反应。它的产品包括Gen-011，这是一种过继的T细胞疗法，正处于治疗实体肿瘤的1/2a阶段临床试验；以及Gen-009，它是一种新抗原候选疫苗，正处于1/2a阶段的临床试验，提供跨越ATLAS识别的抗肿瘤新抗原的辅助性合成长肽。该公司成立于2006年，总部设在马萨诸塞州剑桥市。2022年7月5日，Genocea Biosciences，Inc.根据破产法第11章向美国马萨诸塞州地区破产法院提交了自愿重组请愿书。
About Creative Medical Technology
关于创新医疗技术
(Get Rating)
(获取评级)
Creative Medical Technology Holdings, Inc., a biotechnology company, focuses on immunology, urology, orthopedics, and neurology using adult stem cell treatments. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; StemSpine to treat chronic lower back pain; ImmCelz for the treatment of stroke patients; and OvaStem for treatment of female infertility. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.
Creative Medical Technology Holdings，Inc.是一家生物技术公司，专注于免疫学、泌尿学、整形外科和使用成人干细胞治疗的神经学。该公司提供CiverStem用于治疗勃起功能障碍；FemCelz用于治疗生殖器敏感性丧失和干燥；StemSpine用于治疗慢性下腰痛；ImmCelz用于治疗中风患者；以及OvaStem用于治疗女性不孕症。创新医疗技术控股公司总部设在亚利桑那州凤凰城。
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
接受Genocea生物科学日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Genocea Biosciences和相关公司的最新新闻和分析师评级的每日简要摘要。
译文内容由第三方软件翻译。